# US 2025/0108082 A1 · Therapeutic combinations for inflammatory conditions and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0108082 A1
- Document ID: US20250108082A1
- Status: Published application
- Kind: A1
- Application number: 18/840,761
- Filed: 2024-02-20
- Published: 2025-04-03
- Earliest claimed: 2023-02-17
- Assignees: Native Code Bio, LLC
- Applicants: Native Code Bio, LLC
- Inventors: Adam R. Nelson; Stephen Y. Hung
- Web page: https://patentgrep.com/patent/US20250108082A1

## CPC

- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61K 36/078: {Psilocybe}
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 36/04: Rhodophycota or rhodophyta (red algae), e.g. Porphyra
- A61K 36/3482: {Cannabis}
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are therapeutic combinations, pharmaceutical compositions, and pharmaceutical kits comprising fungi (e.g., Psilocybe spp. fungi), plants (e.g., Cannabis spp., Dipteryx spp.), and algae (e.g., from the family Bangicaeae, including Pyropia spp. and Porphyra spp.), including extracts and bioactive molecules derived therefrom. Methods of producing the disclosed combinations, compositions, and kits are also provided, such as using natural, biosynthetic, or synthetic means. Further provided are methods of using the disclosed combinations, compositions, and kits in the treatment of medical conditions, and in particular for treating inflammatory diseases and conditions, for which the disclosed combinations are demonstrated to provide significant advantages.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of preventing or treating an inflammatory condition or disorder, comprising administering to a subject having the inflammatory condition or disorder a therapeutic combination comprising:
a. a fungal portion, which comprises a Psilocybe cubensis extract;
b. a first plant portion, which comprises a Cannabis sativa extract;
c. a second plant portion, which comprises a Dipteryx odorata extract; and
d. an algal portion, which comprises a Pyropia yezoensis extract.

### Claim at position 3

18-20. (canceled)

### Claim 21 (depends on 17)

The method of claim 17, wherein the Psilocybe cubensis extract comprises psilocybin and psilocin.

### Claim 22 (depends on 21)

The method of claim 21, wherein the Psilocybe cubensis extract comprises psilocybin and psilocin in a weight ratio from about 1:5 to about 5:1.

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The method of claim 21, wherein the Psilocybe cubensis extract comprises from about 50 μg to about 500 μg of psilocybin and from about 20 μg to about 200 μg of psilocin.

### Claim at position 8

25-26. (canceled)

### Claim 27 (depends on 17)

The method of claim 17, wherein the Cannabis sativa extract comprises Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

### Claim 28 (depends on 27)

The method of claim 27, wherein the Cannabis sativa extract comprises THC and CBD in a weight ratio from about 1:5 to about 5:1.

### Claim 29

(canceled)

### Claim 30 (depends on 27)

The method of claim 27, wherein the Cannabis sativa extract comprises from about 0.1 mg to about 5 mg of THC and from about 0.1 mg to about 5 mg of CBD.

### Claim at position 13

31-32. (canceled)

### Claim 33 (depends on 17)

The method of claim 17, wherein the Dipteryx odorata extract comprises coumarin.

### Claim 34 (depends on 17)

The method of claim 17, wherein the Dipteryx odorata extract comprises from about 1 mg to about 10 mg of coumarin.

### Claim 35

(canceled)

### Claim 36 (depends on 17)

The method of claim 17, wherein the combination comprises from about 1 mg to about 20 mg of Pyropia yezoensis extract.

### Claim at position 18

37-38. (canceled)

### Claim 39 (depends on 17)

The method of claim 17, wherein the Pyropia yezoensis extract comprises porphyran.

### Claim 40 (depends on 17)

The method of claim 17, wherein any one of the Psilocybe cubensis extract, Cannabis sativa extract, Dipteryx odorata extract, and Pyropia yezoensis extract is administered in a separate composition.

### Claim 41

(canceled)

### Claim 42 (depends on 17)

The method of claim 17, wherein the Psilocybe cubensis extract, Cannabis sativa extract, Dipteryx odorata extract, and Pyropia yezoensis extract are administered in a single composition.

### Claim at position 23

43-50. (canceled)

### Claim 51 (depends on 42)

The method of claim 42, wherein the single composition further comprises any of a flavorant, a colorant, and a diluent.

### Claim 52 (depends on 51)

The method of claim 51, wherein the flavorant or the colorant comprises ginger or bay laurel.

### Claim at position 26

53-55. (canceled)

### Claim 56 (depends on 51)

The method of claim 51, wherein the diluent is water.

### Claim at position 28

57-58. (canceled)

### Claim 59 (depends on 42)

The method of claim 42, comprising administering between about 10 mg and about 200 mg of the single composition per single dose.

### Claim at position 30

60-62. (canceled)

### Claim 63 (depends on 17)

The method of claim 17, wherein the subject experiences a reduction in the severity of a symptom of the inflammatory condition or disorder.

### Claim 64

(canceled)

### Claim 65 (depends on 17)

The method of claim 17, wherein the inflammatory condition or disorder is any of long COVID, rheumatoid arthritis, psoriatic arthritis, reactive arthritis, tendonitis, gout, scleroderma, systemic scleroderma, localized scleroderma, CREST syndrome, sciatica, neuropathy, peripheral neuropathy, hereditary neuropathy, acquired neuropathy, motor neuropathy, sensory neuropathy, autonomic neuropathy, combination neuropathy, sciatic neuritis, myalgic encephalomyelitis, Chronic Fatigue Syndrome (CFS), fatty liver disease, endometriosis, type 1 diabetes mellitus, type 2 diabetes mellitus, inflammatory bowel disease, asthma, obesity, cancer, Kawasaki's disease, vasculitis, Uveitis, Crohn's disease, ulcerative colitis, meningitis, allergies, psoriasis, Hashimoto's Disease, Guillain Barre Syndrome, hepatitis, Celiac Disease, multiple sclerosis, fibromyalgia, lupus, and Sjogren's syndrome.

### Claim 66 (depends on 17)

The method of claim 17, wherein the inflammatory condition or disorder is any of long COVID, CREST syndrome, psoriatic arthritis, Hashimoto's disease, multiple sclerosis, sciatica, peripheral neuritis, post-treatment Lyme disease (PTLD)/chronic Lyme disease (CLD) syndrome, chronic fatigue and immune dysfunction syndrome (CFIDS)/chronic fatigue syndrome (CFS), and an inflammatory skin condition.

### Claim at position 35

67-210. (canceled)
